- Home
- VRNA
VRNA
Verona Pharma plc
as 11-15-2024 4:00pm EST
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
| Founded: | 2005 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 2.2B | IPO Year: | 2017 |
| Target Price: | $43.83 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.39 - $40.13 | Next Earning Date: | 11-04-2024 |
| Revenue: | $5,624,000 | Revenue Growth: | 1127.95% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 554.09% |
Stock Insider Trading Activity of Verona Pharma plc (VRNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| EBSWORTH DAVID R | VRNA | Director | Nov 6 '24 | Buy | $4.80 | 39,360 | $188,880.77 | 920,003 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | Nov 1 '24 | Sell | $4.38 | 141,032 | $618,657.57 | 15,298,896 | |
| Hahn Mark W | VRNA | Chief Financial Officer | Nov 1 '24 | Sell | $4.38 | 129,672 | $568,386.66 | 14,374,520 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | Oct 23 '24 | Sell | $4.38 | 144,816 | $633,895.84 | 15,298,896 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | Oct 18 '24 | Sell | $4.38 | 514,152 | $2,253,236.58 | 15,298,896 | |
| Hahn Mark W | VRNA | Chief Financial Officer | Oct 18 '24 | Sell | $4.38 | 525,768 | $2,303,772.76 | 14,374,520 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | Sep 11 '24 | Sell | $3.76 | 600,000 | $2,254,320.00 | 15,298,896 | |
| Hahn Mark W | VRNA | Chief Financial Officer | Sep 11 '24 | Sell | $3.76 | 600,000 | $2,254,080.00 | 14,374,520 |
Latest Verona Pharma plc News
VRNA Breaking Stock News: Dive into VRNA Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Verona Pharma Insider Sold Shares Worth $568,387, According to a Recent SEC Filing
MT Newswires
12 days ago
Verona Pharma Insider Sold Shares Worth $618,658, According to a Recent SEC Filing
Simply Wall St.
12 days ago
Verona Pharma (NASDAQ:VRNA) shareholder returns have been incredible, earning 724% in 5 years
GuruFocus.com
12 days ago
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs
GlobeNewswire
12 days ago
Verona Pharma to Present at Jefferies London Healthcare Conference
MT Newswires
13 days ago
Verona Pharma's Q3 Loss Widens
GlobeNewswire
13 days ago
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GuruFocus.com
16 days ago
Verona Pharma PLC (VRNA) Q3 2024 Earnings Report Preview: What To Expect
Compare VRNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRNA Verona Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.